Sun Pharmaceutical Industries has established an endowed professorship at Mount Sinai to advance dermatologic care, according to an announcement distributed through PR Newswire.

The endowed chair creates a permanent academic position within Mount Sinai's dermatology program, a funding structure that guarantees long-term institutional support independent of annual budget cycles. Endowed professorships of this type typically allow the holder to pursue research, clinical innovation and teaching with sustained financial backing from the gift's principal.

What does the partnership cover?

The announcement names two parties: Sun Pharma, one of the world's largest specialty generic pharmaceutical companies and the maker of an established dermatology portfolio, and the Mount Sinai Health System in New York, whose dermatology department operates clinical and research programs across inflammatory skin disease, skin cancer and complex medical dermatology.

The release positions the professorship as a vehicle to advance dermatologic care. Sun Pharma has built a substantial presence in dermatology therapeutics, and the Mount Sinai commitment extends that engagement from product development into academic medicine.

Industry-funded endowed chairs are a familiar mechanism in US academic dermatology, where pharmaceutical manufacturers including manufacturers of psoriasis, eczema and acne therapies have historically supported university positions, fellowships and research centers. These arrangements pair corporate funding with institutional oversight designed to preserve academic independence.

Why does an endowed chair matter?

An endowed professorship differs from a grant or sponsorship in durability. The corpus of the gift is held in perpetuity, and investment income from it funds the position year after year. For a dermatology department, that stability supports:

• Recruitment and retention of senior faculty
• Long-running clinical research programs
• Training of the next generation of dermatologists
• Continuity of specialized patient care

Mount Sinai's dermatology group treats medically complex skin disease and participates in clinical research. A permanently funded chair adds capacity the department can plan around for decades.

For Sun Pharma, the arrangement deepens ties to a leading academic medical center in a therapeutic area the company has identified as a strategic focus.

What comes next?

The announcement did not specify the appointment timeline, the financial value of the endowment, or the individual who will hold the chair. Mount Sinai and Sun Pharma are expected to release further details as the position is filled and its research agenda takes shape, and the dermatology community will watch whether the partnership expands into funded research programs beyond the chair itself.